Evropska unija - slovenščina - EMA (European Medicines Agency)

bayer animal health gmbh - imidacloprid, moxidectin - antiparazitni izdelki, insekticidi in repelenti - dogs; cats; ferrets - dogsfor psi, ki trpijo ali na tveganje, mešani parazitske okužbe:zdravljenje in preprečevanje bolh okužbe (ctenocephalides felis),zdravljenje grize lice (trichodectes canis),zdravljenje uho tropilaelaps okužbe (otodectes cynotis), sarcoptic mange (zaradi sarcoptes scabiei var. canis), demodicosis (zaradi demodex canis),preprečevanje heartworm bolezni (l3 in l4 ličinke dirofilaria immitis),zdravljenje, ki kroži microfilariae (dirofilaria immitis),zdravljenje kožne dirofilariosis (za odrasle faze dirofilaria repens)preprečevanje kožne dirofilariosis (l3 ličinke dirofilaria repens),zmanjšanje obtoku microfilariae (dirofilaria repens),preprečevanje angiostrongylosis (l4 ličinke in nezreli odraslimi angiostrongylus vasorum),zdravljenje angiostrongylus vasorum in crenosoma vulpis,preprečevanje spirocercosis (spirocerca lupi),zdravljenje eucoleus (syn. capillaria) boehmi (odrasli),zdravljenje oči črv thelazia callipaeda (odrasli),zdravljenje okužb z prebavil nematodes (l4 ličinke, nezreli odraslih od toxocara canis, ancylostoma caninum in uncinaria stenocephala, odraslimi toxascaris leonina in trichuris vulpis). izdelek se lahko uporablja kot del strategije zdravljenja alergijskega dermatitisa bolh (fad). catsfor mačke, ki trpijo ali na tveganje, mešani parazitske okužbe:zdravljenje in preprečevanje bolh okužbe (ctenocephalides felis),zdravljenje uho tropilaelaps okužbe (otodectes cynotis),zdravljenje notoedric mange (notoedres cati),zdravljenje lungworm eucoleus aerophilus (syn. capillaria aerophila) (odrasli),preprečevanje lungworm bolezni (l3/l4 ličinke aelurostrongylus abstrusus),zdravljenje lungworm aelurostrongylus abstrusus (odrasli),zdravljenje oči črv thelazia callipaeda (odrasli),preprečevanje heartworm bolezni (l3 in l4 ličinke dirofilaria immitis),zdravljenje okužb z prebavil nematodes (l4 ličinke, nezreli odraslih od toxocara cati in ancylostoma tubaeforme). izdelek se lahko uporablja kot del strategije zdravljenja alergijskega dermatitisa bolh (fad). ferretsfor bele dihurje, ki trpijo ali na tveganje, mešani parazitske okužbe:zdravljenje in preprečevanje bolh okužbe (ctenocephalides felis),preprečevanje heartworm bolezni (l3 in l4 ličinke dirofilaria immitis).

Evropska unija - slovenščina - EMA (European Medicines Agency)

laboratorios hipra, s.a. - v živo vidni nalezljive bursal bolezni virus (ibdv), sev 1052 - immunologicals za aves, domačo kokošjo, Živo virusna cepiva, ptic nalezljive bursal bolezni virus (bolezni gumboro) - chicken; embryonated chicken eggs - za aktivno imunizacijo 1-dan-stare pitovnih piščancev in embryonated pitovnih kokošja jajca za zmanjšanje kliničnih znakov bolezni in poškodb od bursa od fabricius, ki jih povzročajo zelo virulentni aviarne nalezljive bursal bolezni, okužbe z virusom.

Evropska unija - slovenščina - EMA (European Medicines Agency)

orion corporation - tasipimidine sulfate - other hypnotics and sedatives - psi - alleviation of situational anxiety and fear in dogs triggered by e. travel, noise, owner departure, veterinary visits.

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

gentian generics limited - gliklazid - tableta s prirejenim sproščanjem - gliklazid 30 mg / 1 tableta - gliklazid

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

bioveta -

Evropska unija - slovenščina - EMA (European Medicines Agency)

csl behring gmbh - etranacogene dezaparvovec - hemofilija b - other hematological agents - treatment of severe and moderately severe haemophilia b (congenital factor ix deficiency) in adult patients without a history of factor ix inhibitors.

Evropska unija - slovenščina - EMA (European Medicines Agency)

sanofi winthrop industrie - teriflunomide - multiple skleroza - selektivni imunosupresivi - aubagio is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).

Evropska unija - slovenščina - EMA (European Medicines Agency)

astrazeneca ab - dapagliflozin propandiol monohidrat - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - zdravila, ki se uporabljajo pri diabetesu - type 2 diabetes mellitusedistride is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. poleg drugimi zdravili za zdravljenje diabetesa tipa 2. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 in 5. heart failureedistride is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseedistride is indicated in adults for the treatment of chronic kidney disease.

Evropska unija - slovenščina - EMA (European Medicines Agency)

astrazeneca ab - dapagliflozin propandiol monohidrat - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - zdravila, ki se uporabljajo pri diabetesu - type 2 diabetes mellitusforxiga is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. poleg drugimi zdravili za zdravljenje diabetesa tipa 2. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 in 5. heart failureforxiga is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseforxiga is indicated in adults for the treatment of chronic kidney disease.

Evropska unija - slovenščina - EMA (European Medicines Agency)

astrazeneca ab - olaparib - ovarijske neoplazme - antineoplastična sredstva - ciste na cancerlynparza je označen kot monotherapy za:vzdrževanje zdravljenje odraslih bolnikov z napredovalim (figo fazah iii in iv) brca1/2-mutiral (germline in/ali somatski) high-grade epitelnih jajčnikov, fallopian tube ali primarni trebušno raka, ki so v odziv (popolna ali delna) po koncu prve vrstice platinum, ki temelji kemoterapijo. maintenance treatment of adult patients with platinum sensitive relapsed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy. lynparza in combination with bevacizumab is indicated for the:maintenance treatment of adult patients with advanced (figo stages iii and iv) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (hrd) positive status defined by either a brca1/2 mutation and/or genomic instability (see section 5. breast cancerlynparza is indicated as:monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline brca1/2-mutations who have her2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy (see sections 4. 2 in 5. monotherapy for the treatment of adult patients with germline brca1/2-mutations, who have her2 negative locally advanced or metastatic breast cancer. bolniki morajo imeti predhodno že bili zdravljeni z anthracycline in taxane v (neo)adjuvant ali metastatskim nastavitev, če bolniki niso bili primerni za temi postopki (glej točko 5. bolniki z hormon receptorjev (hr)-pozitivnega raka dojk, je treba tudi napredovala na ali po predhodnem endokrine terapije, ali neprimerna za endokrine terapija. adenocarcinoma of the pancreaslynparza is indicated as:monotherapy for the maintenance treatment of adult patients with germline brca1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen. prostate cancerlynparza is indicated as:monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mcrpc) and brca1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent. in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with mcrpc in whom chemotherapy is not clinically indicated (see section 5.